Search Within

Helena Alexandra Yu

Formats
  1. Meeting Abstract (162)
  2. Journal Article (109)
  3. Editorial (9)
  4. Review (7)
  5. Book Section (2)
  6. Correspondence (2)
  7. Conference Paper (1)
Groups
  1. Department of Medicine (292)
  2. Solid Tumor Oncology Division (292)
  3. Thoracic Oncology (292)
  4. GSK Faculty (121)
  5. Department of Pathology and Laboratory Medicine (105)
  6. Human Oncology and Pathogenesis Program (102)

More Groups

People
  1. Gregory Riely (108)
  2. Mark Kris (95)
  3. Marc Ladanyi (71)
  4. Charles Rudin (58)
  5. Maria Arcila (56)
  6. Alexander Drilon (36)

More People

Years
  1. 2025 (21)
  2. 2024 (28)
  3. 2023 (30)
  4. 2022 (33)
  5. 2021 (30)
  6. 2020 (15)

More Years

Publications
  1. Journal of Clinical Oncology (75)
  2. Journal of Thoracic Oncology (63)
  3. Annals of Oncology (27)
  4. Clinical Cancer Research (18)
  5. International Journal of Radiation Oncology, Biology, Physics (14)
  6. Cancer Discovery (9)

More Publications

Publishers
  1. Elsevier Inc. (86)
  2. American Society of Clinical Oncology (85)
  3. American Association for Cancer Research (31)
  4. Oxford University Press (31)
  5. Nature Publishing Group (12)
  6. Elsevier Science, Inc. (7)

More Publishers

Results (292)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers
    Journal Article

    Offin, M.; Feldman, D.; Ni, A.; Myers, M. L.; Lai, W. V.; Pentsova, E.; Boire, A.; Daras, M.; Jordan, E. J.; Solit, D. B.; more...
    Cancer (2019)

    Fulltext@MSK | Save
  • Lesion-level response dynamics to programmed cell death protein (PD-1) blockade
    Journal Article

    Osorio, J. C.; Arbour, K. C.; Le, D. T.; Durham, J. N.; Plodkowski, A. J.; Halpenny, D. F.; Ginsberg, M. S.; Sawan, P.; Crompton, J. G.; Yu, H. A.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • ORCHARD: A phase II platform study in patients with advanced NSCLC who have progressed on first-line osimertinib therapy
    Meeting Abstract

    Yu, H.; Goldberg, S.; Le, X.; Piotrowska, Z.; Smith, P.; Mensi, I.; Kirova, B.; Chmielecki, J.; Li-Sucholeicki, X.; Szekeres, P.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Tissue-based molecular and histologic landscape of acquired resistance to osimertinib in patients with EGFR-mutant lung cancers
    Meeting Abstract

    Schoenfeld, A.; Chan, J.; Rizvi, H.; Somwar, R.; Kubota, D.; Daneshbod, Y.; Chang, J.; Offin, M.; Arcila, M.; Pe'Er, D.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Preliminary phase 1 results of U3-1402: A novel HER3-targeted antibody-drug conjugate-in EGFR TKI-resistant, EGFR-mutant NSCLC
    Meeting Abstract

    Yu, H.; Johnson, M.; Steuer, C.; Vigliotti, M.; Chen, S.; Kamai, Y.; Yu, C.; Janne, P.
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • A multicenter phase 1/2a trial of CLN-081 in NSCLC with EGFR exon 20 insertion mutations
    Meeting Abstract

    Piotrowska, Z.; Planchard, D.; Clancy, M.; Witter, D.; Zawel, L.; Yu, H.
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Biomarker testing in LA disease
    Meeting Abstract

    Yu, H.
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
    Journal Article

    Hastings, K.; Yu, H. A.; Wei, W.; Sanchez-Vega, F.; DeVeaux, M.; Choi, J.; Rizvi, H.; Lisberg, A.; Truini, A.; Lydon, C. A.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Lessons learned from routine, targeted assessment of liquid biopsies for EGFR T790M resistance mutation in patients with EGFR mutant lung cancers
    Journal Article

    Mondaca, S.; Offin, M.; Borsu, L.; Myers, M.; Josyula, S.; Makhnin, A.; Shen, R.; Riely, G. J.; Rudin, C. M.; Ladanyi, M.; more...
    Acta Oncologica (2019)

    Fulltext@MSK | Save
  • A phase 1/2 study of osimertinib and bevacizumab as initial treatment for patients with metastatic EGFR-mutant lung cancers
    Meeting Abstract

    Yu, H. A.; Kim, R.; Makhnin, A.; Ahn, L. S. H.; Ni, A.; Hayes, S. A.; Young, R. J.; Riely, G. J.; Kris, M. G.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save